Abdominal superficial ultrasound-guided interventional treatment for short-term efficacy and its impact on immune levels in patients with advanced pancreatic cancer
10.3969/j.issn.1000-484X.2025.07.008
- VernacularTitle:腹部浅表超声引导下介入治疗中晚期胰腺癌的近期疗效及其对患者免疫水平的影响
- Author:
Jun WANG
1
;
Lu JIANG
;
Qin XIONG
;
Honghao LUO
Author Information
1. 岳池县人民医院超声科,广安 638300
- Publication Type:Journal Article
- Keywords:
Abdominal superficial ultrasound;
Interventional treatment;
Microwave ablation;
Pancreatic cancer;
Generalized estimating equation
- From:
Chinese Journal of Immunology
2025;41(7):1586-1592,中插1-中插3
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate short-term efficacy of interventional treatment guided by abdominal superficial ultrasound and its impact on immune levels in patients with advanced pancreatic cancer.Methods:A total of 152 patients diagnosed with advanced pancreatic cancer from May 2018 to March 2020 in the People's Hospital of Yuechi were selected as study subjects,with 84 patients treated with combination chemotherapy and 68 patients treated with chemotherapy alone.After 1∶1 propensity score match-ing,a total of 60 patients were included in each group.Clinical data were compared between matched groups,and effect of different treatment methods on short-term efficacy and immune levels in advanced pancreatic cancer were evaluated by generalized estimating equations.Results:There were no statistically significant differences in age,BMI,tumor location,gender,tumor size and tumor stage between matched groups(P>0.05).When comparing efficacy of matched groups,local control rate(LCR)showed a declining trend after treatment(P<0.05),median durations of local progression-free survival(LPFS)and overall survival(OS)in chemotherapy group were higher than monotherapy group(P<0.05).There was no statistically significant difference in CA19-9 level before treatment between combination chemotherapy group and monotherapy chemotherapy group(P>0.05).In combiuation chemotherapy group,CA19-9 level showed a continuous downward trend after treatment,with a significant decrease at 6-month follow-up compared to be-fore treatment;in chemotherapy alone group,CA19-9 level showed an overall decrease followed by an increase,with the lowest point at 1 month,and a significant decrease compared to before treatment,while no significant differences in remaining follow-up periods(P>0.05).There was no significant difference of CA19-9 level at 7 days and 14 days after treatment between monotherapy chemotherapy group and combination chemotherapy group(P>0.05).However,at 1 month,3 months and 6 months after treatment,CA19-9 level in combination chemotherapy group was significantly lower than monotherapy chemotherapy group(P<0.05).Immune levels in combina-tion chemotherapy group showed an initial increase followed by a decrease,reaching the highest point at 1 month,and total T-cell count showed a significant decrease after 6 months of treatment compared to before treatment(P<0.05).CD3+T,NK,IL-2 and IFN-γ immune levels were still higher than before treatment(P<0.05),with no significant differences in remaining indicators compared to before treatment(P>0.05).CD4+T/CD8+T in chemotherapy alone group did not show a significant trend,and remaining indicators showed same trend as combined chemotherapy group(P<0.05);after 6 months of treatment,total T-cell count,CD3+T cell count,NK cell count and IL-2 level were lower than before treatment(P<0.05),with no significant differences in remaining indicators compared to before treatment(P>0.05).During follow-up period,combined chemotherapy group showed higher levels of total T cells,CD3+T cells,NK cells,IL-2,IFN-γ and IL-6 levels compared to single chemotherapy group(P>0.05).CD4+T/CD8+T at 14 days and 3 months of follow-up was significantly higher in combined chemotherapy group than single chemotherapy group(P<0.05),while differences were not significant at other follow-up times(P>0.05).Generalized estimating equation evaluation showed that all indica-tors were statistically significant.Conclusion:Interventional treatment guided by abdominal superficial ultrasound can effectively improve short-term efficacy and immune levels in patients with advanced pancreatic cancer.
